Global economic uncertainty and potential growth downgrades due to ongoing geopolitical conflicts in the Middle East, which may lead to increased investor risk aversion and impact funding for clinical-stage biotechnology companies like BioAge.

Inflationary pressures and rising operational costs, potentially exacerbated by higher oil prices stemming from global conflicts, could affect BioAge's research and development budgets given its current unprofitable status.

The broader interest rate environment and challenges in securing capital for unprofitable biotechs. Although BioAge recently completed a significant public offering, sustained high interest rates could affect future funding rounds and investor appetite for growth-oriented, pre-profit companies.